Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1711-1726
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1711
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1711
Table 3 Details of surgical and pathological results in the original samples before matching and after propensity score match in the two groups
| Original samples | PSM | |||||
| non-CC group (n = 124) | CC group (n = 126) | P value | non-CC group (n = 100) | CC group (n = 96) | P value | |
| Interval time (d) | 0.015 | 0.410 | ||||
| mean (SD) | 71.7 (21.9) | 77.9 (18.6) | 74.5 (20.1) | 76.8 (18.7) | ||
| Surgical method, n (%) | 0.232 | 0.990 | ||||
| APR | 42 (33.9) | 31 (24.6) | 30 (30.0) | 29 (30.2) | ||
| LAR | 77 (62.1) | 91 (72.2) | 66 (66.0) | 63 (65.6) | ||
| Hartmann | 5 (4.0) | 4 (3.2) | 4 (4.0) | 4 (4.2) | ||
| Surgery time (h) | 0.684 | 0.953 | ||||
| mean (SD) | 3.0 (1.3) | 3.1 (1.4) | 3.0 (1.3) | 3.0 (1.4) | ||
| Blood loss (mL) | 0.345 | 0.407 | ||||
| mean (SD) | 75.4 (51.4) | 105.4 (145.5) | 74.5 (47.8) | 99.3 (105.0) | ||
| R0, n (%) | 123 (99.2) | 124 (98.4) | 0.571 | 99 (99.0) | 94 (97.9) | 0.537 |
| Numbers of dissected lymph nodes | 0.194 | 0.502 | ||||
| mean (SD) | 9.1 (4.9) | 8.3 (5.0) | 9 (4.8) | 8.54 (5.0) | ||
| pT satge, n (%) | 0.400 | 0.136 | ||||
| T0 | 21 (16.9) | 31 (24.6) | 17 (17.0) | 28 (29.2) | ||
| T1 | 6 (4.8) | 10 (7.0) | 5 (5.0) | 9 (9.4) | ||
| T2 | 41 (33.1) | 34 (27.0) | 32 (32.0) | 28 (29.2) | ||
| T3 | 54 (43.5) | 50 (39.7) | 44 (44.0) | 30 (31.2) | ||
| T4 | 2 (1.6) | 1 (0.8) | 2 (2.0) | 1 (1.0) | ||
| pN stage, n (%) | 0.541 | 0.712 | ||||
| N0 | 90 (72.6) | 99 (78.6) | 72 (72.0) | 74 (77.1) | ||
| N1 | 26 (21.0) | 21 (16.7) | 22 (22.0) | 17 (17.7) | ||
| N2 | 8 (6.5) | 6 (4.8) | 6 (6.0) | 5 (5.2) | ||
| TRG, n (%) | 0.123 | 0.015 | ||||
| 0 | 21 (16.9) | 31 (24.6) | 17 (17.0) | 28 (29.1) | ||
| 1 | 43 (34.7) | 51 (40.5) | 33 (33.0) | 41 (42.7) | ||
| 2 | 59 (47.6) | 42 (33.3) | 49 (49.0) | 26 (27.1) | 0.176 | |
| 3 | 1 (0.8) | 2 (1.6) | 1 (1.0) | 1 (1.1) | ||
| pT0-2N0, n (%) | 57 (46.0) | 66 (52.4) | 0.311 | 46 (46.0) | 57 (59.4) | 0.061 |
| pCR, n (%) | 18 (14.5) | 27 (21.4) | 0.155 | 14 (14.0) | 24 (25.0) | 0.051 |
- Citation: Sheng XQ, Wang HZ, Li S, Zhang YZ, Geng JH, Zhu XG, Quan JZ, Li YH, Cai Y, Wang WH. Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study. World J Gastrointest Oncol 2022; 14(9): 1711-1726
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1711.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1711